Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. Nagafuji K, et al. Among authors: miyamoto t. J Hematol Oncol. 2013 Feb 6;6:14. doi: 10.1186/1756-8722-6-14. J Hematol Oncol. 2013. PMID: 23388549 Free PMC article.
Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, Akashi K, Harada M. Eto T, et al. Among authors: miyamoto t. Int J Hematol. 2013 Aug;98(2):186-96. doi: 10.1007/s12185-013-1378-9. Epub 2013 Jun 11. Int J Hematol. 2013. PMID: 23754766
Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.
Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Miyamoto T, et al. Int J Hematol. 2018 Apr;107(4):468-477. doi: 10.1007/s12185-017-2389-8. Epub 2017 Dec 14. Int J Hematol. 2018. PMID: 29243031 Clinical Trial.
Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Henzan H, Takase K, Kamimura T, Mori Y, Yoshimoto G, Iwasaki H, Nagafuji K, Ogawa R, Eto T, Uchida N, Fujisaki T, Kato K, Minami M, Kikushige Y, Akashi K, Miyamoto T; Fukuoka Blood & Marrow Transplantation Group (FBMTG). Henzan H, et al. Among authors: miyamoto t. Int J Hematol. 2020 Sep;112(3):349-360. doi: 10.1007/s12185-020-02911-z. Epub 2020 Jun 10. Int J Hematol. 2020. PMID: 32524309
Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K, Miyamoto T, Eto T, Ogawa R, Okumura H, Takase K, Kawano N, Miyazaki Y, Fujisaki T, Wake A, Ohno Y, Kurokawa T, Kamimura T, Takamatsu Y, Yokota S, Akashi K. Nagafuji K, et al. Among authors: miyamoto t. Eur J Haematol. 2019 Sep;103(3):164-171. doi: 10.1111/ejh.13268. Epub 2019 Jul 5. Eur J Haematol. 2019. PMID: 31132205
Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study.
Mori Y, Sasaki K, Ito Y, Kuriyama T, Ueno T, Kadowaki M, Aoki T, Sugio T, Yoshimoto G, Kato K, Maeda T, Nagafuji K, Akashi K, Miyamoto T; Fukuoka Blood and Marrow Transplantation Group. Mori Y, et al. Among authors: miyamoto t. Ann Hematol. 2021 Jan;100(1):197-208. doi: 10.1007/s00277-020-04310-0. Epub 2020 Nov 5. Ann Hematol. 2021. PMID: 33150464
Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.
Morishige S, Miyamoto T, Eto T, Uchida N, Kamimura T, Miyazaki Y, Ogawa R, Okumura H, Fujisak T, Iwasaki H, Kawano N, Wake A, Ohta T, Takamatsu Y, Kurokawa T, Ito Y, Maeda T, Akashi K, Nagafuji K. Morishige S, et al. Among authors: miyamoto t. Int J Hematol. 2021 Jun;113(6):815-822. doi: 10.1007/s12185-021-03116-8. Epub 2021 Mar 16. Int J Hematol. 2021. PMID: 33725318 Clinical Trial.
4,208 results